Neurodegenerative Disorders Drug Development Pipeline Review, 2017

Date: March 21, 2017
Pages: 797
Price:
US$ 3,995.00
License [?]:
Publisher: GBI Research
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N206C57501CEN
Leaflet:

Download PDF Leaflet

Neurodegenerative Disorders Drug Development Pipeline Review, 2017
Neurodegenerative Disorders Drug Development Pipeline Review, 2017

SUMMARY

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability. Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

There are over 1,400 products in active development in the neurodegenerative disorders therapy area. The current market landscape consists of a number of biologics and small molecules, while the pipeline also consists of gene therapies and cell therapies, demonstrating broader pharmaceutical research and development.

Small molecule drugs dominate the pipeline, with approximately 64% of total pipeline molecules. In comparison, the number of biologics in the pipeline is much lower, representing approximately 26% of the pipeline. Overall the neurodegenerative disorders pipeline is large, with a substantial proportion of products being early-stage assets at the Preclinical development stage.

The report provides comprehensive information on the pipeline development landscape for is Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic lateral sclerosis and Multiple sclerosis, from Discovery through to the Pre-registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

SCOPE
  • Which companies are the most active within the pipeline for neurodegenerative disorders?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
REASONS TO BUY
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


NOTE: Out of security concerns GBI Research requires using corporate email address.
GBI Research Report Guidance
Executive Summary
Introduction
Neurodegenerative Disorders Report Coverage
Alzheimer's Disease Overview
Amyotrophic Lateral Sclerosis Overview
Huntington Disease Overview
Multiple Sclerosis Overview
Parkinson's Disease Overview
Therapeutics Development
Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Multiple Sclerosis
Parkinson's Disease
Therapeutics under Development by Companies
Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Multiple Sclerosis
Parkinson's Disease
Therapeutics under Investigation by Universities/Institutes
Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Multiple Sclerosis
Parkinson's Disease
Pipeline Products Glance
Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Multiple Sclerosis
Parkinson's Disease
Products under Development by Companies
Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Multiple Sclerosis
Parkinson's Disease
Products under Investigation by Universities/Institutes
Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Multiple Sclerosis
Parkinson's Disease
Companies Involved in Therapeutics Development
Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Multiple Sclerosis
Parkinson's Disease
Therapeutics Assessment
Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Multiple Sclerosis
Parkinson's Disease
Dormant Projects
Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Multiple Sclerosis
Parkinson's Disease
Discontinued Products
Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Multiple Sclerosis
Parkinson's Disease
Product Development Milestones
Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Huntington Disease
Multiple Sclerosis
Parkinson's Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Alzheimer's Disease
Number of Products under Development for Alzheimer's Disease – Comparative Analysis
Number of Products under Development for Amyotrophic Lateral Sclerosis
Number of Products under Development for Amyotrophic Lateral Sclerosis – Comparative Analysis
Number of Products under Development for Huntington Disease
Number of Products under Development for Huntington Disease – Comparative Analysis
Number of Products under Development for Multiple Sclerosis
Number of Products under Development for Multiple Sclerosis – Comparative Analysis
Number of Products under Development for Parkinson's Disease
Number of Products under Development for Parkinson's Disease – Comparative Analysis
Number of Products under Development by Companies, Alzheimer's Disease
Number of Products under Development by Companies, Amyotrophic Lateral Sclerosis
Number of Products under Development by Companies, Huntington Disease
Number of Products under Development by Companies, Multiple Sclerosis
Number of Products under Development by Companies, Parkinson's Disease
Number of Products under Investigation by Universities/Institutes, Alzheimer's Disease
Number of Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis
Number of Products under Investigation by Universities/Institutes, Huntington Disease
Number of Products under Investigation by Universities/Institutes, Multiple Sclerosis
Number of Products under Investigation by Universities/Institutes, Parkinson's Disease
Comparative Analysis by Late Stage Development, Alzheimer's Disease
Comparative Analysis by Clinical Stage Development, Alzheimer's Disease
Comparative Analysis by Early Stage Development, Alzheimer's Disease
Comparative Analysis by Unknown Stage Development, Alzheimer's Disease
Comparative Analysis by Late Stage Development, Amyotrophic Lateral Sclerosis
Comparative Analysis by Clinical Stage Development, Amyotrophic Lateral Sclerosis
Comparative Analysis by Early Stage Development, Amyotrophic Lateral Sclerosis
Comparative Analysis by Unknown Stage Development, Amyotrophic Lateral Sclerosis
Comparative Analysis by Late Stage Development, Huntington Disease
Comparative Analysis by Clinical Stage Development, Huntington Disease
Comparative Analysis by Early Stage Development, Huntington Disease
Comparative Analysis by Late Stage Development, Multiple Sclerosis
Comparative Analysis by Clinical Stage Development, Multiple Sclerosis
Comparative Analysis by Early Stage Development, Multiple Sclerosis
Comparative Analysis by Unknown Stage Development, Multiple Sclerosis
Comparative Analysis by Late Stage Development, Parkinson's Disease
Comparative Analysis by Clinical Stage Development, Parkinson's Disease
Comparative Analysis by Early Stage Development, Parkinson's Disease
Comparative Analysis by Unknown Stage Development, Parkinson's Disease
Products under Development by Companies, Alzheimer's Disease
Products under Development by Companies, Amyotrophic Lateral Sclerosis
Products under Development by Companies, Huntington Disease
Products under Development by Companies, Multiple Sclerosis
Products under Development by Companies, Parkinson's Disease
Products under Investigation by Universities/Institutes, Alzheimer's Disease
Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis
Products under Investigation by Universities/Institutes, Huntington Disease
Products under Investigation by Universities/Institutes, Multiple Sclerosis
Products under Investigation by Universities/Institutes, Parkinson's Disease
Alzheimer's Disease – Pipeline by AB Science SA,
Alzheimer's Disease – Pipeline by AbbVie Inc,
Alzheimer's Disease – Pipeline by AC Immune SA,
Alzheimer's Disease – Pipeline by Accera, Inc.,
Alzheimer's Disease – Pipeline by Acelot, Inc.,
Alzheimer's Disease – Pipeline by Actinogen Limited,
Alzheimer's Disease – Pipeline by Acumen Pharmaceuticals, Inc.,
Alzheimer's Disease – Pipeline by Addex Therapeutics Ltd,
Alzheimer's Disease – Pipeline by Affibody AB,
Alzheimer's Disease – Pipeline by AFFiRiS AG,
Alzheimer's Disease – Pipeline by Alector LLC,
Alzheimer's Disease – Pipeline by Alkermes Plc,
Alzheimer's Disease – Pipeline by Allergan Plc,
Alzheimer's Disease – Pipeline by Allinky Biopharma,
Alzheimer's Disease – Pipeline by ALSP, Inc.,
Alzheimer's Disease – Pipeline by Alzhyme Pty Ltd,
Alzheimer's Disease – Pipeline by Alzinova AB,
Alzheimer's Disease – Pipeline by AlzProtect SAS,
Alzheimer's Disease – Pipeline by Amarantus Bioscience Holdings, Inc.,
Alzheimer's Disease – Pipeline by Amgen Inc.,
Alzheimer's Disease – Pipeline by Anavex Life Sciences Corp.,
Alzheimer's Disease – Pipeline by Aphios Corporation,
Alzheimer's Disease – Pipeline by Apodemus AB,
Alzheimer's Disease – Pipeline by Applied Research using OMIC Sciences, S.L.,
Alzheimer's Disease – Pipeline by Araclon Biotech, S.L.,
Alzheimer's Disease – Pipeline by Archer Pharmaceuticals, Inc.,
Alzheimer's Disease – Pipeline by ArmaGen Inc.,
Alzheimer's Disease – Pipeline by Artery Therapeutics, Inc.,
Alzheimer's Disease – Pipeline by AskAt Inc.,
Alzheimer's Disease – Pipeline by Astellas Pharma Inc.,
Alzheimer's Disease – Pipeline by AstraZeneca Plc,
Alzheimer's Disease – Pipeline by Asubio Pharma Co., Ltd.,
Alzheimer's Disease – Pipeline by Ausio Pharmaceuticals, LLC,
Alzheimer's Disease – Pipeline by Avineuro Pharmaceuticals, Inc.,
Alzheimer's Disease – Pipeline by Axon Neuroscience SE,
Alzheimer's Disease – Pipeline by Axovant Sciences Ltd.,
Alzheimer's Disease – Pipeline by Axsome Therapeutics, Inc.,
Alzheimer's Disease – Pipeline by Axxam SpA,
Alzheimer's Disease – Pipeline by Beactica AB,
Alzheimer's Disease – Pipeline by Berg LLC,
Alzheimer's Disease – Pipeline by BioArctic Neuroscience AB,
Alzheimer's Disease – Pipeline by Bioasis Technologies Inc.,
Alzheimer's Disease – Pipeline by Biogen Inc,
Alzheimer's Disease – Pipeline by Biomar Microbial Technologies,
Alzheimer's Disease – Pipeline by Bionature E.A. Ltd.,
Alzheimer's Disease – Pipeline by Boehringer Ingelheim GmbH,
Alzheimer's Disease – Pipeline by Bristol-Myers Squibb Company,
Alzheimer's Disease – Pipeline by Bsim2,
Alzheimer's Disease – Pipeline by Cardax Pharmaceuticals, Inc.,
Alzheimer's Disease – Pipeline by Carna Biosciences, Inc.,
Alzheimer's Disease – Pipeline by Celon Pharma Sp. z o.o.,
Alzheimer's Disease – Pipeline by CHA Bio & Diostech Co., Ltd.,
Alzheimer's Disease – Pipeline by Chase Pharmaceuticals Corporation,
Alzheimer's Disease – Pipeline by Clera Inc.,
Alzheimer's Disease – Pipeline by Cognition Therapeutics, Inc.,
Alzheimer's Disease – Pipeline by Cognosci, Inc.,
Alzheimer's Disease – Pipeline by CohBar, Inc.,
Alzheimer's Disease – Pipeline by Connexios Life Sciences Pvt. Ltd.,
Alzheimer's Disease – Pipeline by ContraVir Pharmaceuticals, Inc.,
Alzheimer's Disease – Pipeline by Corium International, Inc.,
Alzheimer's Disease – Pipeline by Coronis Partners Ltd.,
Alzheimer's Disease – Pipeline by Cortice Biosciences, Inc.,
Alzheimer's Disease – Pipeline by Critical Outcome Technologies Inc.,
Alzheimer's Disease – Pipeline by Crossbeta Biosciences B.V.,
Alzheimer's Disease – Pipeline by D-Pharm Ltd.,
Alzheimer's Disease – Pipeline by Daewoong Pharmaceutical Co., Ltd.,
Alzheimer's Disease – Pipeline by Daiichi Sankyo Company, Limited,
Alzheimer's Disease – Pipeline by Daval International Limited,
Alzheimer's Disease – Pipeline by DermaXon, LLC,
Alzheimer's Disease – Pipeline by Dongkook Pharmaceutical Co., Ltd.,
Alzheimer's Disease – Pipeline by Eisai Co., Ltd.,
Alzheimer's Disease – Pipeline by Eli Lilly and Company,
Alzheimer's Disease – Pipeline by Emergent BioSolutions Inc.,
Alzheimer's Disease – Pipeline by EncephRx, Inc.,
Alzheimer's Disease – Pipeline by Endece, LLC,
Alzheimer's Disease – Pipeline by ENKAM Pharmaceuticals A/S,
Alzheimer's Disease – Pipeline by Ensemble Therapeutics Corporation,
Alzheimer's Disease – Pipeline by Ensol Biosciences Inc.,
Alzheimer's Disease – Pipeline by Epigen Biosciences, Inc.,
Alzheimer's Disease – Pipeline by Euroscreen S.A.,
Alzheimer's Disease – Pipeline by Evotec AG,
Alzheimer's Disease – Pipeline by F. Hoffmann-La Roche Ltd.,
Alzheimer's Disease – Pipeline by FORUM Pharmaceuticals Inc.,
Alzheimer's Disease – Pipeline by Genentech, Inc.,
Alzheimer's Disease – Pipeline by Genervon Biopharmaceuticals, LLC,
Alzheimer's Disease – Pipeline by GlaxoSmithKline Plc,
Alzheimer's Disease – Pipeline by GliaCure Inc.,
Alzheimer's Disease – Pipeline by Glialogix, Inc.,
Alzheimer's Disease – Pipeline by Golden Biotechnology Corp.,
Alzheimer's Disease – Pipeline by Grifols, S.A.,
Alzheimer's Disease – Pipeline by H. Lundbeck A/S,
Alzheimer's Disease – Pipeline by Heptares Therapeutics Limited,
Alzheimer's Disease – Pipeline by HitGen LTD,
Alzheimer's Disease – Pipeline by Humanetics Corporation,
Alzheimer's Disease – Pipeline by Ichor Medical Systems, Inc.,
Alzheimer's Disease – Pipeline by Icure Pharmaceutical Inc.,
Alzheimer's Disease – Pipeline by Immungenetics AG,
Alzheimer's Disease – Pipeline by Impel NeuroPharma, Inc.,
Alzheimer's Disease – Pipeline by ImStar Therapeutics Inc.,
Alzheimer's Disease – Pipeline by Inovio Pharmaceuticals, Inc.,
Alzheimer's Disease – Pipeline by IntelGenx Corp.,
Alzheimer's Disease – Pipeline by Intellect Neurosciences, Inc.,
Alzheimer's Disease – Pipeline by Intra-Cellular Therapies, Inc.,
Alzheimer's Disease – Pipeline by INVENT Pharmaceuticals, Inc.,
Alzheimer's Disease – Pipeline by Io Therapeutics, Inc.,
Alzheimer's Disease – Pipeline by Iproteos S.L.,
Alzheimer's Disease – Pipeline by Jeil Pharmaceutical Co., Ltd.,
Alzheimer's Disease – Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd.,
Alzheimer's Disease – Pipeline by Johnson & Johnson,
Alzheimer's Disease – Pipeline by K-Stemcell Co., Ltd.,
Alzheimer's Disease – Pipeline by Kadmon Corporation, LLC,
Alzheimer's Disease – Pipeline by Kalgene Pharmaceuticals Inc.,
Alzheimer's Disease – Pipeline by Kareus Therapeutics, SA,
Alzheimer's Disease – Pipeline by KineMed, Inc.,
Alzheimer's Disease – Pipeline by Krenitsky Pharmaceuticals Inc.,
Alzheimer's Disease – Pipeline by Kyowa Hakko Kirin Co., Ltd.,
Alzheimer's Disease – Pipeline by Lead Discovery Center GmbH,
Alzheimer's Disease – Pipeline by Les Laboratoires Servier SAS,
Alzheimer's Disease – Pipeline by Lipopharma Therapeutics SL,
Alzheimer's Disease – Pipeline by Living Cell Technologies Limited,
Alzheimer's Disease – Pipeline by Lupin Limited,
Alzheimer's Disease – Pipeline by M3 Biotechnology, Inc.,
Alzheimer's Disease – Pipeline by ManRos Therapeutics,
Alzheimer's Disease – Pipeline by MedDay SA,
Alzheimer's Disease – Pipeline by Medestea Research & Production S.p.A.,
Alzheimer's Disease – Pipeline by MedImmune, LLC,
Alzheimer's Disease – Pipeline by Medisyn Technologies, Inc.,
Alzheimer's Disease – Pipeline by MEDRx Co., Ltd.,
Alzheimer's Disease – Pipeline by Merck & Co., Inc.,
Alzheimer's Disease – Pipeline by Metabolic Solutions Development Company, LLC,

LIST OF FIGURES

Number of Products under Development for Alzheimer's Disease
Number of Products under Development for Alzheimer's Disease – Comparative Analysis
Number of Products under Development for Amyotrophic Lateral Sclerosis
Number of Products under Development for Amyotrophic Lateral Sclerosis – Comparative Analysis
Number of Products under Development for Huntington Disease
Number of Products under Development for Huntington Disease – Comparative Analysis
Number of Products under Development for Multiple Sclerosis
Number of Products under Development for Multiple Sclerosis – Comparative Analysis
Number of Products under Development for Parkinson's Disease
Number of Products under Development for Parkinson's Disease – Comparative Analysis
Number of Products under Development by Companies, Alzheimer's Disease
Number of Products under Development by Companies, Amyotrophic Lateral Sclerosis
Number of Products under Development by Companies, Huntington Disease
Number of Products under Development by Companies, Multiple Sclerosis
Number of Products under Development by Companies, Parkinson's Disease
Number of Products under Investigation by Universities/Institutes, Alzheimer's Disease
Number of Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis
Number of Products under Investigation by Universities/Institutes, Huntington Disease
Number of Products under Investigation by Universities/Institutes, Multiple Sclerosis
Number of Products under Investigation by Universities/Institutes, Parkinson's Disease
Comparative Analysis by Late Stage Development, Alzheimer's Disease
Comparative Analysis by Clinical Stage Development, Alzheimer's Disease
Comparative Analysis by Early Stage Products, Alzheimer's Disease
Comparative Analysis by Late Stage Development, Amyotrophic Lateral Sclerosis
Comparative Analysis by Clinical Stage Development, Amyotrophic Lateral Sclerosis
Comparative Analysis by Early Stage Products, Amyotrophic Lateral Sclerosis
Comparative Analysis by Late Stage Development, Huntington Disease
Comparative Analysis by Clinical Stage Development, Huntington Disease
Comparative Analysis by Early Stage Products, Huntington Disease
Comparative Analysis by Late Stage Development, Multiple Sclerosis
Comparative Analysis by Clinical Stage Development, Multiple Sclerosis
Comparative Analysis by Early Stage Products, Multiple Sclerosis
Comparative Analysis by Late Stage Development, Parkinson's Disease
Comparative Analysis by Clinical Stage Development, Parkinson's Disease
Comparative Analysis by Early Stage Products, Parkinson's Disease
Comparative Analysis by Unknown Stage Development, Parkinson's Disease
Assessment by Monotherapy Products, Alzheimer's Disease
Assessment by Combination Products, Alzheimer's Disease
Number of Products by Top 10 Targets, Alzheimer's Disease
Number of Products by Stage and Top 10 Targets, Alzheimer's Disease
Number of Products by Top 10 Mechanism of Actions, Alzheimer's Disease
Number of Products by Stage and Top 10 Mechanism of Actions, Alzheimer's Disease
Number of Products by Top 10 Routes of Administration, Alzheimer's Disease
Number of Products by Stage and Top 10 Routes of Administration, Alzheimer's Disease
Number of Products by Top 10 Molecule Types, Alzheimer's Disease
Number of Products by Stage and Top 10 Molecule Types, Alzheimer's Disease
Assessment by Monotherapy Products, Amyotrophic Lateral Sclerosis
Assessment by Combination Products, Amyotrophic Lateral Sclerosis
Number of Products by Top 10 Targets, Amyotrophic Lateral Sclerosis
Number of Products by Stage and Top 10 Targets, Amyotrophic Lateral Sclerosis
Number of Products by Top 10 Mechanism of Actions, Amyotrophic Lateral Sclerosis
Number of Products by Stage and Top 10 Mechanism of Actions, Amyotrophic Lateral Sclerosis
Number of Products by Top 10 Routes of Administration, Amyotrophic Lateral Sclerosis
Number of Products by Stage and Top 10 Routes of Administration, Amyotrophic Lateral Sclerosis
Number of Products by Top 10 Molecule Types, Amyotrophic Lateral Sclerosis
Number of Products by Stage and Top 10 Molecule Types, Amyotrophic Lateral Sclerosis
Assessment by Monotherapy Products, Huntington Disease
Number of Products by Top 10 Targets, Huntington Disease
Number of Products by Stage and Top 10 Targets, Huntington Disease
Number of Products by Top 10 Mechanism of Actions, Huntington Disease
Number of Products by Stage and Top 10 Mechanism of Actions, Huntington Disease
Number of Products by Top 10 Routes of Administration, Huntington Disease
Number of Products by Stage and Top 10 Routes of Administration, Huntington Disease
Number of Products by Top 10 Molecule Types, Huntington Disease
Number of Products by Stage and Top 10 Molecule Types, Huntington Disease
Assessment by Monotherapy Products, Multiple Sclerosis
Number of Products by Top 10 Targets, Multiple Sclerosis
Number of Products by Stage and Top 10 Targets, Multiple Sclerosis
Number of Products by Top 10 Mechanism of Actions, Multiple Sclerosis
Number of Products by Stage and Top 10 Mechanism of Actions, Multiple Sclerosis
Number of Products by Top 10 Routes of Administration, Multiple Sclerosis
Number of Products by Stage and Top 10 Routes of Administration, Multiple Sclerosis
Number of Products by Top 10 Molecule Types, Multiple Sclerosis
Number of Products by Stage and Top 10 Molecule Types, Multiple Sclerosis
Assessment by Monotherapy Products, Parkinson's Disease
Assessment by Combination Products, Parkinson's Disease
Number of Products by Top 10 Targets, Parkinson's Disease
Number of Products by Stage and Top 10 Targets, Parkinson's Disease
Number of Products by Top 10 Mechanism of Actions, Parkinson's Disease
Number of Products by Stage and Top 10 Mechanism of Actions, Parkinson's Disease
Number of Products by Top 10 Routes of Administration, Parkinson's Disease
Number of Products by Stage and Top 10 Routes of Administration, Parkinson's Disease
Number of Products by Top 10 Molecule Types, Parkinson's Disease
Number of Products by Stage and Top 10 Molecule Types, Parkinson's Disease
Skip to top


Ask Your Question

Neurodegenerative Disorders Drug Development Pipeline Review, 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: